Prediction of inter-individual variability in the pharmacokinetics of CYP2C19 substrates in humans

Drug Metabolism and Pharmacokinetics

Volumn 29, Issue 5, 2014, Pages 379-386

  Chiba, Koji ^a,b,c   Shimizu, Keiko ^d   Kato, Motohiro ^e   Nishibayashi, Takaaki ^b   Terada, Kazuki ^a   Izumo, Nobuo ^a   Sugiyama, Yuichi ^c  

^a YOKOHAMA COLLEGE OF PHARMACY   (Japan)

^b KEIO UNIVERSITY   (Japan)

^c RIKEN   (Japan)

^d KYORIN PHARMACEUTICAL CO LTD   (Japan)

^e CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

CYP2C19; Drug development; Human pharmacokinetics; Inter individual variability; Monte Carlo simulation; Pharmacogenetics

Indexed keywords

CYTOCHROME P450 2C19; LANSOPRAZOLE; OMEPRAZOLE; RABEPRAZOLE; CYP2C19 PROTEIN, HUMAN;

AREA UNDER THE CURVE; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DRUG CLEARANCE; GENOTYPE; HUMAN; IN VIVO STUDY; INTER INDIVIDUAL VARIABILITY; LIVER CLEARANCE; LIVER METABOLISM; MATHEMATICAL COMPUTING; MAXIMUM PLASMA CONCENTRATION; OUTCOME ASSESSMENT; PREDICTION; STATISTICAL PARAMETERS; GENETIC POLYMORPHISM; GENETICS; METABOLISM; MONTE CARLO METHOD;

AREA UNDER CURVE; CYTOCHROME P-450 CYP2C19; GENOTYPE; HUMANS; LANSOPRAZOLE; MONTE CARLO METHOD; POLYMORPHISM, GENETIC; RABEPRAZOLE;

EID: 84908249654     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-13-RG-137     Document Type: Article

References (54)

1. Tomalik-Scharte, D., Lazar, A., Fuhr, U. and Kirchheiner, J.: The clinical role of genetic polymorphisms in drug-metabolizing enzymes. Pharmacogenomics, 8: 4-15 (2007).
2. Kurose, K., Sugiyama, E. and Saito, Y.: Population differences in major functional polymorphisms of pharmacokinetics/pharmacodynamics-related genes in Eastern Asians and Europeans: Implications in the clinical trials for novel drug development. Drug Metab. Pharmacokinet., 27: 9-54 (2012).
3. Shimizu, T., Ochiai, H., A˚sell, F., Yokono, Y., Kikuchi, Y., Nitta, M., Hama, Y., Yamagichi, S., Hashimoto, M., et al.: Bioinformatics research on inter-racial difference in drug metabolism II. Analysis on relationship between enzyme activities of CYP2D6 and CYP2C19 and their relevant genotypes. Drug Metab. Pharmacokinet., 18: 71-78 (2003).
4. Furuta, T., Sugimoto, M. and Shirai, N.: Individualized therapy for Gastroesophageal Reflux Disease: Potential impact of pharmacogenetic testing based on CYP2C19. Mol. Diagn. Ther., 16: 223-234 (2012).
5. Furuta, T., Sugimoto, M., Shirai, N. and Ishizaki, T.: CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and Gastroesophageal Reflux Diseases with a proton pump inhibitor. Pharmacogenomics, 8: 1199-1210 (2007).
6. Sibbing, D., Koch, W., Gebhard, D., Schuster, T., Braun, S., Stegherr, J., Morath, T., Schömig, A., von Beckerath, N., et al.: Cytochrome 2C19∗ 17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation, 121: 512-518 (2010).
7. Chiba, K., Kato, M., Ito, T., Suwa, T. and Sugiyama, Y.: Inter-individual variability of in vivo CYP2D6 activity in different genotypes. Drug Metab. Pharmacokinet., 27: 405-413 (2012).
8. Kato, M., Chiba, K., Ito, T., Koue, T. and Sugiyama, Y.: Prediction of interindividual variability in pharmacokinetics for CYP3A4 substrates in humans. Drug Metab. Pharmacokinet., 25: 367-378 (2010).
9. Thummel, K. E. and Shen, D. D.: Design and optimization of dosage regimens: pharmacokinetic data. In Gilman, A. and Goodman, L. S. (eds.). The Pharmacological Basis of Therapeutics, 10th ed., McGraw-Hill Medical Publishing Division, New York, 2011, pp. 1917-2024.
10. Thummel, K. E., Shen, D. D., Isoherranen, N. and Smith, H. E.: Design and optimization of dosage regimens: pharmacokinetic data. In Gilman, A. G., Brunton, L. L., Gilman, A., Goodman, L. S., Lazo, J. S. and Parker, K. L. (eds.). The Pharmacological Basis of Therapeutics, 11th ed., McGraw-Hill Medical Publishing Division, New York, 2006, pp. 1787-1888.
11. Thummel, K. E., Shen, D. D. and Isoherranen, N.: Design and optimization of dosage regimens: pharmacokinetic data. In Brunton, L. L., Goodman, L. S., Chabner, B. A. and Knollmann, B. C. (eds.). The Pharmacological Basis of Therapeutics, 12th ed., McGraw-Hill Medical Publishing Division, New York, 2011, pp. 1891-1990.
12. Roberts, M. S. and Rowland, M.: Correlation between in-vitro microsomal enzyme activity and whole organ hepatic elimination kinetics: analysis with a dispersion model. J. Pharm. Pharmacol., 38: 177-181 (1986).
13. Naritomi, Y., Terashita, S., Kagayama, A. and Sugiyama, Y.: Utility of hepatocytes in predicting drug metabolism: comparison of hepatic intrinsic clearance in rats and humans in vivo and in vitro. Drug Metab. Dispos., 31: 580-588 (2003).
14. Shibata, Y., Takahashi, H., Chiba, M. and Ishii, Y.: A novel approach to the prediction of drug-drug interactions in humans based on the serum incubation method. Drug Metab. Pharmacokinet., 23: 328-339 (2008).
15. Uchimura, T., Kato, M., Saito, T. and Kinoshita, H.: Prediction of human blood-to-plasma drug concentration ratio. Biopharm. Drug Dispos., 31: 286-297 (2010).
16. Yasuda, S., Ohnishi, T., Ogawa, T., Tomono, Y., Hasegawa, J., Nakai, H., Simamura, Y. and Morishita, N.: Pharmacokinetic properties of E3810, a new proton pump inhibitor, in healthy male volunteers. Int. J. Clin. Pharmacol. Ther., 32: 466-473 (1994).
17. Wynne, H. A., Cope, L. H., Mutch, E., Rawlins, M. D., Woodhouse, K. W. and James, O. F.: The effect of age upon liver volume and apparent liver blood flow in healthy man. Hepatology, 9: 297-301 (2005).
18. Kerremans, A. L. M., Gribnau, F. W. J., Tan, Y. and van Ginneken, C. A. M.: Pharmacokinetic and pharmacodynamic studies of tienilic acid in healthy volunteers. Eur. J. Clin. Pharmacol., 22: 515-521 (1982).
19. Gorski, J. C., Hall, S. D., Becker, P., Affrime, M. B., Cutler, D. L. and Haehner-Daniels, B.: In vivo effects of interleukin-10 on human cytochrome P450 activity. Clin. Pharmacol. Ther., 67: 32-43 (2000).
20. Pirttiaho, H., Sotaniemi, E., Pelkonen, R. and Pitkänen, U.: Hepatic blood flow and drug metabolism in patients on enzyme-inducing anticonvulsants. Eur. J. Clin. Pharmacol., 22: 441-445 (1982).
21. Davis, D., Grossman, S., Kitchell, B. B., Shand, D. and Routledge, P.: The effects of age and smoking on the plasma protein binding of lignocaine and diazepam. Br. J. Clin. Pharmacol., 19: 261-265 (2012).
22. Myrand, S., Sekiguchi, K., Man, M., Lin, X., Tzeng, R., Teng, C., Hee, B., Garrett, M., Kikkawa, H., et al.: Pharmacokinetics/genotype associations for major cytochrome P450 enzymes in native and first- and third-generation Japanese populations: comparison with Korean, Chinese, and Caucasian populations. Clin. Pharmacol. Ther., 84: 347-361 (2008).
23. Poo, J. L., Galán, J. F., Rosete, A., de Lago, A., Oliva, I., González-de la Parra, M., Jiménez, P., Burke-Fraga, V. and Namur, S.: Bioavailability of two single-dose oral formulations of Omeprazole 20 mg: An open-label, randomized sequence, two-period crossover comparison in healthy Mexican adult volunteers. Clin. Ther., 30: 693-699 (2008).
24. Klotz, U.: Pharmacokinetic considerations in the eradication of Helicobacter pylori. Clin. Pharmacokinet., 38: 243-270 (2000).
25. Baldwin, R. M., Ohlsson, S., Pedersen, R. S., Mwinyi, J., Ingelman-Sundberg, M., Eliasson, E. and Bertilsson, L.: Increased omeprazole metabolism in carriers of the CYP2C19∗17 allele; a pharmacokinetic study in healthy volunteers. Br. J. Clin. Pharmacol., 65: 767-774 (2008).
26. Ohlsson Rosenborg, S., Mwinyi, J., Andersson, M., Baldwin, R. M., Pedersen, R. S., Sim, S. C., Bertilsson, L., Ingelman-Sundberg, M. and Eliasson, E.: Kinetics of omeprazole and escitalopram in relation to the CYP2C19∗17 allele in healthy subjects. Eur. J. Clin. Pharmacol., 64: 1175-1179 (2008).
27. Hunfeld, N. G., Mathot, R. A., Touw, D. J., Van Schaik, R. H., Mulder, P. G., Franck, P. F., Kuipers, E. J. and Geus, W. P.: Effect of CYP2C19∗2 and∗ 17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in Caucasians. Br. J. Clin. Pharmacol., 65: 752-760 (2008).
28. Yin, O. Q., Tomlinson, B., Chow, A. H., Waye, M. M. and Chow, M. S.: Omeprazole as a CYP2C19 marker in Chinese subjects: assessment of its gene-dose effect and intrasubject variability. J. Clin. Pharmacol., 44: 582-589 (2004).
29. Furuta, T., Ohashi, K., Kosuge, K., Zhao, X. J., Takashima, M., Kimura, M., Nishimoto, M., Hanai, H., Kaneko, E., et al.: CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. Clin. Pharmacol. Ther., 65: 552-561 (1999).
30. Qiao, H. L., Hu, Y. R., Tian, X., Jia, L. J., Gao, N., Zhang, L. R. and Guo, Y. Z.: Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype. Eur. J. Clin. Pharmacol., 62: 107-112 (2006).
31. Furuta, T., Ohashi, K., Kobayashi, K., Iida, I., Yoshida, H., Shirai, N., Takashima, M., Kosuge, K., Hanai, H., et al.: Effects of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans. Clin. Pharmacol. Ther., 66: 265-274 (1999).
32. He, N., Huang, S. L., Zhu, R. H., Tan, Z. R., Liu, J., Zhu, B. and Zhou, H. H.: Inhibitory effect of troleandomycin on the metabolism of omeprazole is CYP2C19 genotype-dependent. Xenobiotica, 33: 211-221 (2003).
33. Uno, T., Niioka, T., Hayakari, M., Yasui-Furukori, N., Sugawara, K. and Tateishi, T.: Absolute bioavailability and metabolism of omeprazole in relation to CYP2C19 genotypes following single intravenous and oral administrations. Eur. J. Clin. Pharmacol., 63: 143-149 (2007).
34. Tu, J. H., Hu, D. L., Dai, L. L., Sun, Y., Fan, L., Zhang, M., Tan, Z. R., Chen, Y., Li, Z., et al.: Effect of glycyrrhizin on CYP2C19 and CYP3A4 activity in healthy volunteers with different CYP2C19 genotypes. Xenobiotica, 40: 393-399 (2010).
35. Sakai, T., Aoyama, N., Kita, T., Sakaeda, T., Nishiguchi, K., Nishitora, Y., Hohda, T., Sirasaka, D., Tamura, T., et al.: CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects. Pharm. Res., 18: 721-727 (2001).
36. Cho, J. Y., Yu, K. S., Jang, I. J., Yang, B. H., Shin, S. G. and Yim, D. S.: Omeprazole hydroxylation is inhibited by a single dose of moclobemide in homozygotic EM genotype for CYP2C19. Br. J. Clin. Pharmacol., 53: 393-397 (2002).
37. Saito, M., Yasui-Furukori, N., Uno, T., Takahata, T., Sugawara, K., Munakata, A. and Tateishi, T.: Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes. Br. J. Clin. Pharmacol., 59: 302-309 (2005).
38. Yasui-Furukori, N., Saito, M., Uno, T., Takahata, T., Sugawara, K. and Tateishi, T.: Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes. J. Clin. Pharmacol., 44: 1223-1229 (2004).
39. Ieiri, I., Kishimoto, Y., Okochi, H., Momiyama, K., Morita, T., Kitano, M., Morisawa, T., Fukushima, Y., Nakagawa, K., et al.: Comparison of the kinetic disposition of and serum gastrin change by lansoprazole versus rabeprazole during an 8-day dosing scheme in relation to CYP2C19 polymorphism. Eur. J. Clin. Pharmacol., 57: 485-492 (2001).
40. Zalloum, I., Hakooz, N. and Arafat, T.: Genetic polymorphism of CYP2C19 in a Jordanian population: influence of allele frequencies of CYP2C19∗1 and CYP2C19∗2 on the pharmacokinetic profile of lansoprazole. Mol. Biol. Rep., 39: 4195-4200 (2012).
41. Hu, Y., Qiao, H. and Kan, Q.: Pharmacokinetics of lansoprazole in Chinese healthy subjects in relation to CYP2C19 genotypes. Acta Pharmacol. Sin., 25: 986-990 (2004).
42. Iwasaki, K., Ito, Y., Shibata, N., Takada, K., Sakurai, Y., Takagi, N., Irie, S. and Nakamura, K.: Effect of water intake on pharmacokinetics of lansoprazole from fast disintegrating tablet in human subjects. Drug Metab. Pharmacokinet., 19: 390-395 (2004).
43. Takeda Chemical Industries' interview form (5th ed.): Bioequivalence between No.1 capsule and No.3 capsule, Takeda Chemical Industries, Inc, 2011 (in Japanese).
44. Horai, Y., Kimura, M., Furuie, H., Matsuguma, K., Irie, S., Koga, Y., Nagahama, T., Murakami, M., Matsui, T., et al.: Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes. Aliment. Pharmacol. Ther., 15: 793-803 (2001).
45. Niioka, T., Uno, T., Yasui-Furukori, N., Shimizu, M., Sugawara, K. and Tateishi, T.: Identification of the time-point which gives a plasma rabeprazole concentration that adequately reflects the area under the concentration-time curve. Eur. J. Clin. Pharmacol., 62: 855-861 (2006).
46. Shimizu, M., Uno, T., Yasui-Furukori, N., Sugawara, K. and Tateishi, T.: Effects of clarithromycin and verapamil on rabeprazole pharmacokinetics between CYP2C19 genotypes. Eur. J. Clin. Pharmacol., 62: 597-603 (2006).
47. Hu, Y.-M., Xu, J.-M., Mei, Q., Xu, X.-H. and Xu, S.-Y.: Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotype in healthy Chinese subjects. Acta Pharmacol. Sin., 26: 384-388 (2005).
48. Farinha, A., Bica, A., Pais, J., Toscano, M. and Tavares, P.: Bioequivalence evaluation of two omeprazole enteric-coated formulations in humans. Eur. J. Pharm. Sci., 7: 311-315 (1999).
49. Freston, J., Chiu, Y. L., Mulford, D. and Ballard, E. D., 2nd: Comparative pharmacokinetics and safety of lansoprazole oral capsules and orally disintegrating tablets in healthy subjects. Aliment. Pharmacol. Ther., 17: 361-367 (2003).
50. Amer, F., Karol, M. D., Pan, W. J., Griffin, J. S., Lukasik, N. L., Locke, C. S. and Chiu, Y. L.: Comparison of the pharmacokinetics of lansoprazole 15- and 30-mg sachets for suspension versus intact capsules. Clin. Ther., 26: 2076-2083 (2004).
51. Chun, A. H. C., Erdman, K., Chiu, Y. L., Pilmer, B. L., Achari, R. and Cavanaugh, J. H.: Bioavailability of lansoprazole granules administered in juice or soft food compared with the intact capsule formulation. Clin. Ther., 24: 1322-1331 (2002).
52. Freston, J., Kukulka, M., Lloyd, E. and Lee, C.: A novel option in proton pump inhibitor dosing: lansoprazole orally disintegrating tablet dispersed in water and administered via nasogastric tube. Aliment. Pharmacol. Ther., 20: 407-411 (2004).
53. Dugger, H. A., Carlson, J. D., Henderson, W., Erdmann, G. R., Alam, S. M., Dham, R. and Quamruzaman: Bioequivalence evaluation of lansoprazole 30-mg capsules (Lanfast® and Lanzor®) in healthy volunteers. Eur. J. Pharm. Biopharm., 51: 153-157 (2001).
54. Vlase, L., Popa, A., Neag, M., Muntean, D. and Leucuta, S. E.: Effect of Fluoxetine on the pharmacokinetics of Lansoprazole: A two-treatment period dtudy in healthy male subjects. Clin. Drug Investig., 31: 727-733 (2011).